UNSTRUCTURED
This study investigates the most frequently asked questions regarding systemic treatments for psoriasis vulgaris using Google Trends and People Also Asked (PAA) tools, focusing on traditional DMARDs, biologics, and small-molecule inhibitors. Analyzing data from January 31, 2019, to January 31, 2024, Adalimumab was found to have the highest search volume, followed by Apremilast and Methotrexate in their respective categories. Based on Rothwell’s Question Classification Criteria, questions about Adalimumab predominantly centered around their technical, factual details and cost of the medication. The study highlights significant public interest in these factors over their safety profile and it is likely influenced by Adalimumab’s high direct-to-consumer marketing. Moreover, evaluation of 782 websites showed that potential patients were seeking commercial and government-based websites to learn more about systemic psoriasis treatment. According to the JAMA benchmark criteria, these source types also scored the highest in terms of information quality, while medical practice websites scored the lowest. The findings suggest the need for dermatologists to address factual details such as medication administration scheduling, dietary restrictions, and cost during patient consultations, and to guide patients towards high-quality online resources. Limitations include potential comprehensiveness of questions and evolving medication concerns.